Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells

Prostate

Volumn 39, Issue 4, 1999, Pages 269-279

  Denmeade, Samuel R ^a   Lin, Xiaohui S ^b   Tombal, Bertrand ^c   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; FLOXURIDINE; THAPSIGARGIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL COMMUNICATION; CELL INTERACTION; CELL PROTECTION; DEPHOSPHORYLATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SIGNAL TRANSDUCTION;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL SURVIVAL; CLONE CELLS; CYSTEINE PROTEINASE INHIBITORS; ENZYME INHIBITORS; FLOXURIDINE; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; RATS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; THAPSIGARGIN; TUMOR CELLS, CULTURED;

EID: 0033151801     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990601)39:4<269::AID-PROS7>3.0.CO;2-F     Document Type: Article

References (58)

1. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995:267;1456-1462.
2. Isaacs JT. Role of programmed cell death in carcinogenesis. Environ Health Perspect 1993:101;27-34.
3. Kerr JFR, Wyllie AG, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972:26;239-257.
4. Eastman A. Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis. Semin Cancer Biol 1995:6;45-52.
5. Zhivotovsky B, Gahm A, Ankarcrona M, Nicotera P, Orrenius S. Multiple proteases are involved in thymocyte apoptosis. Exp Cell Res 1995:221;404-412.
6. Evan G, Littlewood T. A matter of life and cell death. Science 1998;281:1317-1321.
7. Ashekenazi A, Dixit V. Death receptors: signaling and modulation. Science 1998;281:1305-1308.
8. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281:1309-1312.
9. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998;281:1312-1316.
10. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993:71;1098-1109.
11. Carter HB, Isaacs JT. Experimental and theoretical basis for hormone treatment of prostatic cancer. Semin Urol 1988;6:262-268.
12. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. Implications of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
13. 2+-ATPase. Proc Natl Acad Sci USA 1990;87:2466-2470.
14. Furuya Y, Lundmo P, Short AS, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994;54:6167-6175.
15. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Role of growth arrest in programmed (apoptotic) death of prostate cancer cells by thapsigargin. Prostate 1997;33:201-207.
16. Furuya Y, Isaacs JT. Proliferation-dependent vs. independent programmed cell death of prostatic cancer involves distinct gene regulation. Prostate 1994;25:301-309.
17. 2+], in individual cells undergoing apoptosis. Cell Calcium 1999;25: 19-28.
18. Denmeade SR, Tombal B, Isaacs JT. Apoptotic pathways in prostate cancer. In: Mattson M, editor. Programmed cell death: role in disease, pathogenesis, and prevention. Greenwich: JAI Press, Inc., 1999.
19. Qi M-X, He H, Hongying Z, Distelhorst CW. Baculovirus p35 and Z-VAD-fmk inhibit thapsigargin-induced apoptosis of breast cancer cells. Oncogene 1997;15:1207-1212.
20. Browne SJ, MacFarlane M, Cohen GM, Paraskeva C. The adenomatous polyposis coli protein and retinoblastoma protein are cleaved early in apoptosis and are potential substrates for caspases. Cell Death Differ 1998;5:206-213.
21. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-6.
22. Thornberry NA. The caspase family of cysteine proteases. Br Med Bull 1996;53:478-490.
23. Villa P, Kaufmann SH, Earnshaw WC. Caspases and caspase inhibitors. TIBS 1997;22:00-00.
24. Marcelli M, Cunnigham GR, Haidacher SJ, Padayatty SJ, Sturgis L, Kagan C, Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. Cancer Res 1998;58:76-83.
25. Marcelli M, Cunningham GR, Walkup M, He Z, Sturgis L, Kagan C, Mannuci R, Nicoletti I, Teng B, Denner L. Signaling pathway activated apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res 1999;59:382-390.
26. Bowen C, Spiegel S, Gelmann EP. Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res 1998;58:3275-3281.
27. Zhao X, Gschwend JE, Powell CT, Foster RG, Day KC, Day ML. Retinoblastoma-protein-dependent growth signal conflict and caspase activity are required for protein kinase C-signaled apoptosis of prostate epithelial cells. J Biol Chem 1997;272:22751-22757.
28. Srikanth SD, Kraft AS. Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res 1998;58:834-839.
29. Deveraux QL, Roy N, Stennicke R, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998;17:2215-2223.
30. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321.
31. Miura M, Friedlander RM, Yuan J. Tumor necrosis factor-induced apoptosis is mediated by crmA-sensitive cell death pathway. Proc Natl Acad Sci USA 1995;92:8318-8322.
32. Martikainen P, Kyprianou N, Tucker RW, Isaacs JT. Programmed death of non-proliferating androgen-independent prostatic cancer cells. Cancer Res 1991;51:4693-4700.
33. Iizumi T, Yazaki T, Kanoh S, Kondo I, Koiso K. Establishment of a new prostatic carcinoma cell line (TSU-Pr1). J Urol 1987;137: 1304-1306.
34. Furuya Y, Walsh JC, Lin X, Nelson WG, Isaacs JT. Androgen ablation induced programmed death of prostatic glandular cancer cells does not involve recruitment into a defective cell cycle or p53 induction. Endocrinology 1995;136:1898-1906.
35. Gerlach C, Golding M, Larue L, Alison MR, Gerdes J. Ki-67 immunoexpression is a robust marker of proliferative cells in the rat. Lab Invest 1997;77:697-698.
36. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT. Expression of bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996;2:389-398.
37. Knudsen ES, Wang JY. Dual mechanism for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 1997:17;5771-5783.
38. Chen W-D, Otterson GA, Lipkowitz S, Khleif SN, Coxon AB, Faye FJ. Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding. Oncogene 1997;14:1243-1248.
39. Janicke RU, Walker PA, Lin XY, Porter AG. Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 1996;15:6969-6978.
40. An B, Dou QP. Cleavage of retinoblastoma protein during apoptosis: interleukin-1B-converting enzyme-like protease as candidate. Cancer Res 1996;56:438-442.
41. Fan G, Ma X, Kren BT, Steer CJ. The retinoblastoma gene product inhibits TGF-beta 1 induced apoptosis in primary hepatocytes and human HuH-7 hepatoma cells. Oncogene 1996;12: 1909-1919.
42. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW. A combinatorial approach defines specificities of members of the caspase family and granzyme B. J Biol Chem 1997;272:17907-17911.
43. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Reconstitution of the apoptotic cascade in vitro: pivotal role for prICE, a protease resembling interleukin-1B converting enzyme and demonstration that poly(ADP ribose) polymerase is a substrate for this enzyme during apoptosis. Nature 1994;371:346-347.
44. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG, Specific proteolytic fragmentation of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976-3985.
45. Song Q, Lees-Miller SP, Kumar S, Zhang N, Chan DW, Smith GCM, Jackson SP, Alnemri ES, Litwack G, Khanna KK, Lavin MF. DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis. EMBO J 1996;15:3238-3246.
46. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ, Williams LT. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997;278:294-298.
47. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1996;91:479-489.
48. Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, Elia A, de la Pompa JL, Kagi D, Khoo W, Potter J, Yoshida R, Kaufman SA, Lowe SW, Penninger JM, Mak TW. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998;94:339-352.
49. Kuida K, Haydar TF, Kuan C-Y, Gu Y, Taya C, Karasuyama H, Su MS, Rakic P, Flavell RA. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998;94:325-327.
50. Susin SA, Zamzami N, Castedo M, Daugas E, Wang HG, Geley S, Fassy F, Reed JC, Kroemer G. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95-and ceramide-induced apoptosis. J Exp Med 1997;186:25-37.
51. 1 and DNA fragmentation in isolated thymocyte nuclei. J Biol Chem 1996; 271:22398-22406.
52. Alain-Théophile S, Bertrand R. Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl-and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities. Cancer Res 1998;58:3066-3072.
53. Lazebnik YA, Takahashi A, Moir RD, Goldman RD, Poirier GG, Kaufmann SH, Earnshaw WC. Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution. Proc Natl Acad Sci USA 1995;92:9042-9046.
54. Takahashi A, Musy P-Y, Martins LM, Poirer GG, Moyer RW, Earnshaw WC. CrmA/SPI-2 inhibition of an endogenous ICE-related protease responsible for lamin A cleavage and apoptotic nuclear fragmentation. J Biol Chem 1996;271:32487-32490.
55. Denmeade SR, Isaacs JT. Enzymatic-activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer. Cancer J Sci Am [Suppl] 1998;4:15-21.
56. Christensen SB, Andersen A, Kromann H, Treiman M, Tombal B, Denmeade SR, Isaacs JT. Thapsigargin analogues for targeting programmed death of androgen-independent prostatic cancer cells. Bioorg Med Chem 1998; in press.
57. Denmeade SR, Lou W, Lövgren J, Malm H, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57: 4924-4930.
58. Denmeade SR, Nagy A, Gao J, Lilja H, Schally A, Isaacs JT. Enzymatic-activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 1998;58:2537-2540.